Dainippon Sumitomo Pharma's (DSP) US subsidiary, Sepracor, is to change its operating name to Sunovion Pharmaceuticals by the end of this year.
Dainippon Sumitomo Pharma's (DSP) US subsidiary, Sepracor, is to change its operating name to Sunovion Pharmaceuticals by the end of this year.
The commercial functions and product portfolio of the company will otherwise remain unchanged, and the operation will maintain its current...
Create an account to read this article
Already a subscriber?
The companies announced the publication of Phase III data that they said provide rationale for moving forward in a confirmatory trial.
The Swiss neuroscience specialist has extended its cash runway into late 2027, but will still need positive readouts in the coming months, including for its wholly owned Parkinson’s candidate.
The Phase II study tested AP-101 safety and tolerability as the primary endpoint but showed “clinically meaningful” efficacy in exploratory endpoints.
The US FDA approved a subcutaneous version of the Biogen-partnered anti-amyloid antibody, Leqembi IQLIK, for once-weekly maintenance dosing after 18 months of I.V. treatment every two weeks.
The Phase II study tested AP-101 safety and tolerability as the primary endpoint but showed “clinically meaningful” efficacy in exploratory endpoints.
Seizing an opportunity to buy out struggling 'zombie' biotechs, Xoma is helping to return investor cash and pick up potential bargain assets for itself. Its CEO and chief investment officer explained their approach to Scrip.
The OX40 ligand-targeting drug’s efficacy is seen as light compared with existing therapies.
